Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03842982 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer (CHIPPI)

Study acronym: CHIPPI
StatusActive, Not Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary and study completion dates: Nov 1, 2026 to Feb 1, 2031
    • Start date: Apr 1, 2019 to May 3, 2019
    • Trial status: Recruiting to Active, Not Recruiting
    • Site details revised at 18 of 18 sites
    v7
  2. Study sites: 17 to 18
    • Primary completion date: Aug 1, 2027 to Nov 1, 2026
    • Study completion date: Aug 1, 2028 to Nov 1, 2026
    v6
  3. Re-verified, no change to tracked fieldsv5
  4. Study sites: 15 to 17v4
  5. Primary completion date: Jun 1, 2023 to Aug 1, 2027v3 Show 4 more changesShow less
    • Enrollment target: 432 to 362
    • Study sites: 8 to 15
    • Study completion date: Jun 1, 2024 to Aug 1, 2028
    • Eligibility criteria expanded, about 10 words
  6. Trial status: Not Yet Recruiting to Recruitingv2 Show 4 more changesShow less
    • Primary completion date: Mar 1, 2023 to Jun 1, 2023
    • Study completion date: Mar 1, 2024 to Jun 1, 2024
    • Start date changed from estimate of Mar 1, 2019 to Apr 1, 2019
    • Site details revised at 8 of 8 sites
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a phase III, multicenter, interventional and randomized study which evaluates the use of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) coupled with either Primary Debulking Surgery (PDS) or Interval Debulking Surgery (IDS), in patients with ovarian cancer. This study aims to assess the efficacy, in terms of disease-free survival (DFS), the use of HIPEC combined with standard care (PDS or IDS) or standard care alone.
Trial Details
NCT Number NCT03842982
Lead Sponsor Centre Oscar Lambret
Conditions
(from sponsor)		 Ovary Neoplasms, Ovarian Cancer, Ovarian Carcinoma
Related terms Ovarian Neoplasms
Enrollment 362 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov